Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial

Autor:	Barta, Stefan K., Hamdan, Ayad, Boué, François, Delobel, Pierre, Galicier, Lionel, Coppo, Paul, Ghesquières, Hervé, Rubinstein, Paul G *, Moore, Page C, Bimali, Milan, Lee, Jeanette Y, Rudek, Michelle A, Chadburn, Amy, Ratner, Lee, Henry, David H, Cesarman, Ethel, DeMarco, Camille E, Costagliola, Dominique, Taoufik, Yassine, Ramos, Juan Carlos, Sharon, Elad, Reid, Erin G, Ambinder, Richard F, Mitsuyasu, Ronald, Mounier, Nicolas, Besson, Caroline, Noy, Ariela
Zdroj:	In The Lancet Haematology August 2023 10(8):e624-e632
Databáze:	ScienceDirect
Externí odkaz: